# DRD5

Source: https://onco.cc/targets/drd5/  
OnCo record `drd5` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DRD5 (Dopamine receptor D5) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.

## Summary

G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signalling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. Dopamine receptors can be classified in two categories: (1) DRD5 (together with DRD1) is a D1-type receptor and is coupled to G(s) G proteins, mediating activation of adenylate cyclase activity, while D2-type receptors (DRD2, DRD3 and DRD4) are coupled to G(i)/G(o) G proteins and promote inhibition of adenylate cyclase activity.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Dordaviprone.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: dopamine receptor D5; Dopamine receptor D5; DRD1B; DRD1L2
- Tags: cancer-genes-wave
- Symbol: DRD5
- Class: other
- Biology: G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signalling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. Dopamine receptors can be classified in two categories: (1) DRD5 (together with DRD1) is a D1-type receptor and is coupled to G(s) G proteins, mediating activation of adenylate cyclase activity, while D2-type receptors (DRD2, DRD3 and DRD4) are coupled to G(i)/G(o) G proteins and promote inhibition of adenylate cyclase activity. D1- and D2-type dopamine receptors have antagonistic effects, particularly in the brain's striatum, where they govern voluntary movement and reward: D1-type receptors generally stimulate neural activity and promotes action, while D2-type receptors tend to inhibit neural activity and suppress movement. DRD5 acts as a key regulator of blood pressure: negatively regulates the renin-angiotensin system (RAS), thereby reducing renal sodium absorption by the kidney. Location: Cell membrane (UniProt). Locus 4p16.1 (HGNC).
- Where found: Glioma & glioblastoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3026: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3026
- UniProt P21918: https://www.uniprot.org/uniprotkb/P21918/entry
- NCBI Gene 1816: https://www.ncbi.nlm.nih.gov/gene/1816
- Ensembl ENSG00000169676: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169676

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/drd5.json